{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T11:00:19Z","timestamp":1774090819361,"version":"3.50.1"},"reference-count":84,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UK Medical Research Council","doi-asserted-by":"publisher","award":["MC_U120097115"],"award-info":[{"award-number":["MC_U120097115"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012176","name":"Maudsley Charity","doi-asserted-by":"publisher","award":["666"],"award-info":[{"award-number":["666"]}],"id":[{"id":"10.13039\/100012176","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["094849\/Z\/10\/Z"],"award-info":[{"award-number":["094849\/Z\/10\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Hypothesis<\/jats:title>\n                    <jats:p>Persistent symptoms and disability are common in psychotic disorders. This may be partly attributable to inadequate antipsychotic treatment, but there has not been a recent overview of what constitutes inadequate treatment and its impact on outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Design<\/jats:title>\n                    <jats:p>We focus on the latest meta-analyses to critically appraise the relationship between markers of inadequate antipsychotic treatment and outcomes from the first episode of psychosis onwards, relating outcomes to periods without antipsychotic use, antipsychotic treatment of subtherapeutic dose\/duration, and antipsychotic partial\/non-adherence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Results<\/jats:title>\n                    <jats:p>Inadequate antipsychotic treatment is common (non-adherence rates\u2009=\u200944%-56%), and repeatedly associated with poorer outcomes across several key patient-centered outcomes, including increased risk of relapse (relative risk (RR) up to 2.70, n\u2009=\u200913\u2009988), more severe overall symptoms (standardized mean difference (SMD) up to 0.78, n\u2009=\u20098878), poorer quality-of-life (SMD up to 0.50, n\u2009=\u20091421), poorer functioning (SMD up to 0.55, n\u2009=\u20091988) and higher mortality (RR up to 1.83, n\u2009=\u2009272\u2009030). We also find there is more evidence for schizophrenia than other psychotic disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We identify that there are no operationalized criteria for the minimally adequate treatment of psychosis, in contrast to major depression, for example. We propose that a longer duration of inadequate treatment (DIT) may be an important predictor of outcome, although this has not been tested. To address this and support the development of interventions to reduce inadequate treatment, we propose operationalized criteria for the minimally adequate treatment of psychosis and the DIT, proposing both clinically applicable and research criteria. Finally, we consider future directions for research and practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/schbul\/sbag017","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T10:20:15Z","timestamp":1774088415000},"source":"Crossref","is-referenced-by-count":0,"title":["What is Minimally Adequate Treatment of Psychosis and Should Duration of Inadequate Treatment be a Clinical and Research Target? A Perspective and State-of-the-Art Review"],"prefix":"10.1093","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5462-8464","authenticated-orcid":false,"given":"Martin","family":"Osugo","sequence":"first","affiliation":[{"name":"Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London , London, SE5 8AB ,","place":["United Kingdom"]},{"name":"Psychiatric Imaging Group, Medical Research Council, London Institute of Medical Sciences, Hammersmith Hospital , London, W12 0HS ,","place":["United Kingdom"]},{"name":"South London and Maudsley NHS Foundation Trust , London, SE5 8AZ ,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver D","family":"Howes","sequence":"additional","affiliation":[{"name":"Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London , London, SE5 8AB ,","place":["United Kingdom"]},{"name":"Psychiatric Imaging Group, Medical Research Council, London Institute of Medical Sciences, Hammersmith Hospital , London, W12 0HS ,","place":["United Kingdom"]},{"name":"South London and Maudsley NHS Foundation Trust , London, SE5 8AZ ,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"key":"2026032106200674100_ref1","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","article-title":"Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors","volume":"174","author":"Leucht","year":"2017","journal-title":"Am J Psychiatry"},{"key":"2026032106200674100_ref2","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S0140-6736(21)01997-8","article-title":"Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis","volume":"399","author":"Schneider-Thoma","year":"2022","journal-title":"Lancet."},{"key":"2026032106200674100_ref3","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet."},{"key":"2026032106200674100_ref4","doi-asserted-by":"publisher","first-page":"104568","DOI":"10.1016\/j.neubiorev.2022.104568","article-title":"Dopamine partial agonists and prodopaminergic drugs for schizophrenia: systematic review and meta-analysis of randomized controlled trials","volume":"135","author":"Osugo","year":"2022","journal-title":"Neurosci Biobehav Rev"},{"key":"2026032106200674100_ref5","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1192\/bjp.2023.57","article-title":"Treating negative symptoms of schizophrenia: current approaches and future perspectives","volume":"223","author":"Howes","year":"2023","journal-title":"Br J Psychiatry"},{"key":"2026032106200674100_ref6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/wps.20822","article-title":"The clinical significance of duration of untreated psychosis: an umbrella review and random-effects meta-analysis","volume":"20","author":"Howes","year":"2021","journal-title":"World Psychiatry"},{"key":"2026032106200674100_ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.3430","article-title":"Role of serotonin in the neurobiology of schizophrenia and association with negative symptoms","volume":"83","author":"Osugo","year":"2026","journal-title":"JAMA Psychiatry"},{"key":"2026032106200674100_ref8","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1093\/schbul\/sbae017","article-title":"Duration of untreated psychosis and outcomes in first-episode psychosis: systematic review and meta-analysis of early detection and intervention strategies","volume":"50","author":"Salazar de Pablo","year":"2024","journal-title":"Schizophr Bull"},{"key":"2026032106200674100_ref9","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1176\/appi.ajp.2019.19030324","article-title":"Lead-time bias confounds association between duration of untreated psychosis and illness course in schizophrenia","volume":"177","author":"Jonas","year":"2020","journal-title":"Am J Psychiatry"},{"key":"2026032106200674100_ref10","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/S2215-0366(24)00317-1","article-title":"Service coverage for major depressive disorder: estimated rates of minimally adequate treatment for 204 countries and territories in 2021","volume":"11","author":"Santomauro","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"2026032106200674100_ref11","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology","volume":"174","author":"Howes","year":"2017","journal-title":"Am J Psychiatry"},{"key":"2026032106200674100_ref12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3389\/fpsyt.2019.00067","article-title":"Predictive factors of treatment resistance in first episode of psychosis: a systematic review","volume":"10","author":"Bozzatello","year":"2019","journal-title":"Front Psychiatry"},{"key":"2026032106200674100_ref13","doi-asserted-by":"publisher","first-page":"664","DOI":"10.47626\/1516-4446-2021-2306","article-title":"Long-term effects of antipsychotics on mortality in patients with schizophrenia: a systematic review and meta-analysis","volume":"44","author":"Jia","year":"2022","journal-title":"Braz J Psychiatry"},{"key":"2026032106200674100_ref14","doi-asserted-by":"publisher","first-page":"5033","DOI":"10.1017\/S0033291722002021","article-title":"Discontinuation of antipsychotics in individuals with first-episode schizophrenia and its association to functional outcomes, hospitalization and death: a register-based nationwide follow-up study","volume":"53","author":"Sturup","year":"2023","journal-title":"Psychol Med"},{"key":"2026032106200674100_ref15","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S2215-0366(22)00015-3","article-title":"Real-world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study","volume":"9","author":"Taipale","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"2026032106200674100_ref16","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/S2215-0366(23)00366-8","article-title":"Efficacy and effectiveness of antipsychotics in schizophrenia: network meta-analyses combining evidence from randomised controlled trials and real-world data","volume":"11","author":"Efthimiou","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"2026032106200674100_ref24","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1017\/S0033291718001393","article-title":"Effect of discontinuation v. maintenance of antipsychotic medication on relapse rates in patients with remitted\/stable first-episode psychosis: a meta-analysis","volume":"49","author":"Kishi","year":"2019","journal-title":"Psychol Med"},{"key":"2026032106200674100_ref27","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S2215-0366(22)00158-4","article-title":"Continuing, reducing, switching, or stopping antipsychotics in individuals with schizophrenia-spectrum disorders who are clinically stable: a systematic review and network meta-analysis","volume":"9","author":"Ostuzzi","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"2026032106200674100_ref35","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/S2215-0366(21)00078-X","article-title":"Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials","volume":"8","author":"Hojlund","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"2026032106200674100_ref38","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.schres.2012.05.007","article-title":"Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies","volume":"139","author":"Alvarez-Jimenez","year":"2012","journal-title":"Schizophr Res"},{"key":"2026032106200674100_ref26","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s40263-015-0269-4","article-title":"The use of continuous treatment versus placebo or intermittent treatment strategies in stabilized patients with schizophrenia: a systematic review and meta-analysis of randomized controlled trials with first- and second-generation antipsychotics","volume":"29","author":"De Hert","year":"2015","journal-title":"CNS Drugs"},{"key":"2026032106200674100_ref45","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S2215-0366(21)00039-0","article-title":"Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre&#x2013;post studies","volume":"8","author":"Kishimoto","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"2026032106200674100_ref33","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/schbul\/sbaa063","article-title":"Antipsychotic dose in acute schizophrenia: a meta-analysis","volume":"46","author":"Takeuchi","year":"2020","journal-title":"Schizophr Bull"},{"key":"2026032106200674100_ref46","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1177\/0004867419837358","article-title":"Long-acting atypical antipsychotics in schizophrenia: a systematic review and meta-analyses of effects on functional outcome","volume":"53","author":"Olagunju","year":"2019","journal-title":"Aust N Z J Psychiatry"},{"key":"2026032106200674100_ref17","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/s41467-025-56663-7","article-title":"Striatal dopamine D2\/D3 receptor regulation of human reward processing and behaviour","volume":"16","author":"Osugo","year":"2025","journal-title":"Nat Commun"},{"key":"2026032106200674100_ref18","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"2026032106200674100_ref19","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1038\/s41386-025-02120-4","article-title":"Antipsychotics cause reversible structural brain changes within one week","volume":"50","author":"Selvaggi","year":"2025","journal-title":"Neuropsychopharmacology."},{"key":"2026032106200674100_ref20","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/JCP.0000000000001921","article-title":"Aripiprazole-associated QT prolongation in a healthy study volunteer: a case report and literature review","volume":"44","author":"Chapman","year":"2024","journal-title":"J Clin Psychopharmacol"},{"key":"2026032106200674100_ref21","doi-asserted-by":"publisher","first-page":"5315","DOI":"10.1038\/s41380-025-03116-8","article-title":"Effects of antipsychotics on human cognitive function: causal evidence from healthy volunteers following sustained D2\/D3 antagonism, D2\/D3 partial agonism and placebo","volume":"30","author":"Osugo","year":"2025","journal-title":"Mol Psychiatry"},{"key":"2026032106200674100_ref22","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.biopsych.2015.02.008","article-title":"The effect of antipsychotic treatment on cortical gray matter changes in schizophrenia: does the class matter? A meta-analysis and meta-regression of longitudinal magnetic resonance imaging studies","volume":"78","author":"Vita","year":"2015","journal-title":"Biol Psychiatry"},{"key":"2026032106200674100_ref23","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/j.neubiorev.2013.06.001","article-title":"Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies","volume":"37","author":"Fusar-Poli","year":"2013","journal-title":"Neurosci Biobehav Rev"},{"key":"2026032106200674100_ref25","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1192\/bjo.2018.17","article-title":"Maintenance antipsychotic treatment versus discontinuation strategies following remission from first episode psychosis: systematic review","volume":"4","author":"Thompson","year":"2018","journal-title":"BJPsych Open"},{"key":"2026032106200674100_ref28","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S2215-0366(23)00258-4","article-title":"Antipsychotic dose reduction and discontinuation versus maintenance treatment in people with schizophrenia and other recurrent psychotic disorders in England (the RADAR trial): an open, parallel-group, randomised controlled trial","volume":"10","author":"Moncrieff","year":"2023","journal-title":"Lancet Psychiatry"},{"key":"2026032106200674100_ref29","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1001\/jamapsychiatry.2013.19","article-title":"Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction\/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial","volume":"70","author":"Wunderink","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"2026032106200674100_ref30","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/schbul\/sbu001","article-title":"Dose equivalents for second-generation antipsychotics: the minimum effective dose method","volume":"40","author":"Leucht","year":"2014","journal-title":"Schizophr Bull"},{"key":"2026032106200674100_ref31","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1176\/appi.ajp.2019.19010034","article-title":"Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia","volume":"177","author":"Leucht","year":"2020","journal-title":"Am J Psychiatry"},{"key":"2026032106200674100_ref32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41537-021-00171-2","article-title":"Antipsychotics for negative and positive symptoms of schizophrenia: dose-response meta-analysis of randomized controlled acute phase trials","volume":"7","author":"Sabe","year":"2021","journal-title":"NPJ Schizophr"},{"key":"2026032106200674100_ref34","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1001\/jamapsychiatry.2021.2130","article-title":"Examination of dosing of antipsychotic drugs for relapse prevention in patients with stable schizophrenia: a meta-analysis","volume":"78","author":"Leucht","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"2026032106200674100_ref36","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","article-title":"International consensus study of antipsychotic dosing","volume":"167","author":"Gardner","year":"2010","journal-title":"Am J Psychiatry"},{"key":"2026032106200674100_ref37","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/s41386-019-0573-7","article-title":"Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials","volume":"45","author":"Tani","year":"2020","journal-title":"Neuropsychopharmacology."},{"key":"2026032106200674100_ref39","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1176\/appi.ajp.2010.09010087","article-title":"Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia","volume":"168","author":"Subotnik","year":"2011","journal-title":"Am J Psychiatry"},{"key":"2026032106200674100_ref40","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/wps.20060","article-title":"Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies","volume":"12","author":"Kane","year":"2013","journal-title":"World Psychiatry"},{"key":"2026032106200674100_ref41","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s12888-017-1425-9","article-title":"Experiences of antipsychotic use in patients with early psychosis: a two-year follow-up study","volume":"17","author":"Yeisen","year":"2017","journal-title":"BMC Psychiatry"},{"key":"2026032106200674100_ref42","doi-asserted-by":"publisher","first-page":"56","DOI":"10.9740\/mhc.2018.03.056","article-title":"Evaluation of adherence and persistence with oral versus long-acting injectable antipsychotics in patients with early psychosis","volume":"8","author":"Titus-Lay","year":"2018","journal-title":"Ment Health Clin"},{"key":"2026032106200674100_ref43","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1034\/j.1600-0447.2002.02437.x","article-title":"Medication adherence of individuals with a first episode of psychosis","volume":"106","author":"Coldham","year":"2002","journal-title":"Acta Psychiatr Scand"},{"key":"2026032106200674100_ref44","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40263-021-00815-y","article-title":"Real-world evidence of the clinical and economic impact of long-acting injectable versus Oral antipsychotics among patients with schizophrenia in the United States: a systematic review and meta-analysis","volume":"35","author":"Lin","year":"2021","journal-title":"CNS Drugs"},{"key":"2026032106200674100_ref47","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/YCO.0000000000000160","article-title":"Ambiguous findings concerning potential advantages of depot antipsychotics: in search of clinical relevance","volume":"28","author":"Haddad","year":"2015","journal-title":"Curr Opin Psychiatry"},{"key":"2026032106200674100_ref48","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/j.jclinepi.2013.01.012","article-title":"Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry","volume":"66","author":"Kane","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"2026032106200674100_ref49","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/schbul\/sbs150","article-title":"Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials","volume":"40","author":"Kishimoto","year":"2014","journal-title":"Schizophr Bull"},{"key":"2026032106200674100_ref50","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/YIC.0000000000000082","article-title":"Long-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designs","volume":"30","author":"Bossie","year":"2015","journal-title":"Int Clin Psychopharmacol"},{"key":"2026032106200674100_ref51","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1001\/jamapsychiatry.2020.1596","article-title":"Association of end point definition and randomized clinical trial duration in clinical trials of schizophrenia medications","volume":"77","author":"Younis","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"2026032106200674100_ref52","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/j.biopsych.2005.02.023","article-title":"Early-onset hypothesis of antipsychotic drug action: a hypothesis tested","volume":"57","author":"Leucht","year":"2005","journal-title":"Confirmed and Extended Biological Psychiatry"},{"key":"2026032106200674100_ref53","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1139\/jpn.0611","article-title":"The \"delayed onset\" of antipsychotic action--an idea whose time has come and gone","volume":"31","author":"Agid","year":"2006","journal-title":"J Psychiatry Neurosci"},{"key":"2026032106200674100_ref54","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1192\/bjp.bp.116.186007","article-title":"One-year symptom trajectories in patients with stable schizophrenia maintained on antipsychotics versus placebo: Meta-analysis","volume":"211","author":"Takeuchi","year":"2017","journal-title":"Br J Psychiatry"},{"key":"2026032106200674100_ref55","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13643-020-1274-3","article-title":"Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: a systematic review and meta-analysis","volume":"9","author":"Semahegn","year":"2020","journal-title":"Syst Rev"},{"key":"2026032106200674100_ref56","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jsps.2013.03.003","article-title":"Evaluation of defined daily dose, percentage of British National Formulary maximum and chlorpromazine equivalents in antipsychotic drug utilization","volume":"22","author":"Sweileh","year":"2014","journal-title":"Saudi Pharm J"},{"key":"2026032106200674100_ref57","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.4088\/jcp.v69n1003","article-title":"Patterns of atypical antipsychotic subtherapeutic dosing among Oregon Medicaid patients","volume":"69","author":"Hartung","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"2026032106200674100_ref58","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/s0140-6736(07)61414-7","article-title":"Use of mental health services for anxiety, mood, and substance disorders in 17 countries in the WHO world mental health surveys","volume":"370","author":"Wang","year":"2007","journal-title":"Lancet."},{"key":"2026032106200674100_ref59","doi-asserted-by":"publisher","first-page":"531763","DOI":"10.3389\/fnins.2020.531763","article-title":"Antipsychotic treatment failure: a systematic review on risk factors and interventions for treatment adherence in psychosis","volume":"14","author":"El Abdellati","year":"2020","journal-title":"Front Neurosci"},{"key":"2026032106200674100_ref60","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","article-title":"Remission in schizophrenia: proposed criteria and rationale for consensus","volume":"162","author":"Andreasen","year":"2005","journal-title":"Am J Psychiatry"},{"key":"2026032106200674100_ref61","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1192\/S0007125000297663","article-title":"Early intervention in psychosis. The critical period hypothesis","volume":"172","author":"Birchwood","year":"1998","journal-title":"Br J Psychiatry Suppl"},{"key":"2026032106200674100_ref62","volume-title":"Quality Standard","author":"Psychosis and Schizophrenia in Adults"},{"key":"2026032106200674100_ref63","doi-asserted-by":"publisher","first-page":"s116","DOI":"10.1192\/bjp.187.48.s116","article-title":"Early intervention and recovery for young people with early psychosis: consensus statement","volume":"48","author":"Bertolote","year":"2005","journal-title":"Br J Psychiatry Suppl"},{"key":"2026032106200674100_ref64","doi-asserted-by":"publisher","first-page":"e071984","DOI":"10.1136\/bmjopen-2023-071984","article-title":"Digital health interventions to improve adherence to oral antipsychotics among patients with schizophrenia: a scoping review","volume":"13","author":"Wu","year":"2023","journal-title":"BMJ Open"},{"key":"2026032106200674100_ref65","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0269881119889296","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology","volume":"34","author":"Barnes","year":"2020","journal-title":"J Psychopharmacol"},{"key":"2026032106200674100_ref66","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1192\/bjp.bp.112.116285","article-title":"Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias","volume":"204","author":"Jauhar","year":"2014","journal-title":"Br J Psychiatry"},{"key":"2026032106200674100_ref67","doi-asserted-by":"publisher","first-page":"102392","DOI":"10.1016\/j.eclinm.2023.102392","article-title":"Cognitive behavioural therapy for the treatment of schizophrenia spectrum disorders: an umbrella review of meta-analyses of randomised controlled trials","volume":"67","author":"Berendsen","year":"2024","journal-title":"EClinicalMedicine."},{"key":"2026032106200674100_ref68","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1192\/bjp.2023.21","article-title":"Psychosocial and behavioural interventions for the negative symptoms of schizophrenia: a systematic review of efficacy meta-analyses","volume":"223","author":"Cella","year":"2023","journal-title":"Br J Psychiatry"},{"key":"2026032106200674100_ref69","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41537-022-00248-6","article-title":"The efficacy of transcranial magnetic stimulation (TMS) for negative symptoms in schizophrenia: a systematic review and meta-analysis","volume":"8","author":"Lorentzen","year":"2022","journal-title":"Schizophrenia (Heidelb)"},{"key":"2026032106200674100_ref70","doi-asserted-by":"publisher","first-page":"967941","DOI":"10.3389\/fpsyt.2022.967941","article-title":"The effect of antipsychotics on glutamate levels in the anterior cingulate cortex and clinical response: a (1)H-MRS study in first-episode psychosis patients","volume":"13","author":"Zahid","year":"2022","journal-title":"Front Psychiatry"},{"key":"2026032106200674100_ref71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1192\/bjp.2025.10319","article-title":"The effects of dopamine receptor antagonist and partial agonist antipsychotics on the glutamatergic system: a double-blind, randomised, placebo-controlled 1H-MRS cross-over study in healthy volunteers","author":"Zahid","year":"2025","journal-title":"Br J Psychiatry"},{"key":"2026032106200674100_ref72","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/schbul\/17.2.325","article-title":"Neuroleptics and the natural course of schizophrenia","volume":"17","author":"Wyatt","year":"1991","journal-title":"Schizophr Bull"},{"key":"2026032106200674100_ref73","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1751-7893.2007.00038.x","article-title":"Is untreated psychosis socially toxic?","volume":"1","author":"Norman","year":"2007","journal-title":"Early Intervention in Psychiatry"},{"key":"2026032106200674100_ref74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2019.04.009","article-title":"Neuroprotective effects of the second generation antipsychotics","volume":"208","author":"Chen","year":"2019","journal-title":"Schizophr Res"},{"key":"2026032106200674100_ref75","doi-asserted-by":"publisher","first-page":"383","DOI":"10.4306\/pi.2017.14.4.383","article-title":"Neuroprotection in schizophrenia and its therapeutic implications","volume":"14","author":"Kim","year":"2017","journal-title":"Psychiatry Investig"},{"key":"2026032106200674100_ref76","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1080\/15622975.2024.2366235","article-title":"Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: focus on antipsychotics","volume":"25","author":"Hart","year":"2024","journal-title":"World J Biol Psychiatry"},{"key":"2026032106200674100_ref77","doi-asserted-by":"publisher","first-page":"114997","DOI":"10.1016\/j.psychres.2022.114997","article-title":"Gender differences in the response to antipsychotic medication in patients with schizophrenia: an individual patient data meta-analysis of placebo-controlled studies","volume":"320","author":"Storosum","year":"2023","journal-title":"Psychiatry Res"},{"key":"2026032106200674100_ref78","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/S2215-0366(22)00304-2","article-title":"The response of subgroups of patients with schizophrenia to different antipsychotic drugs: a systematic review and meta-analysis","volume":"9","author":"Leucht","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"2026032106200674100_ref79","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S2215-0366(22)00336-4","article-title":"Is this the end of precision medicine? Or the beginning?","volume":"9","author":"Takamiya","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"2026032106200674100_ref80","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/wps.21036","article-title":"Metabolic side effects in persons with schizophrenia during mid- to long-term treatment with antipsychotics: a network meta-analysis of randomized controlled trials","volume":"22","author":"Burschinski","year":"2023","journal-title":"World Psychiatry"},{"key":"2026032106200674100_ref81","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/wps.20579","article-title":"Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis","volume":"17","author":"Carbon","year":"2018","journal-title":"World Psychiatry"},{"key":"2026032106200674100_ref82","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41537-025-00592-3","article-title":"Predictors of relapse after discontinuing antipsychotics in patients with schizophrenia spectrum disorders","volume":"11","author":"Li","year":"2025","journal-title":"Schizophrenia (Heidelb)"},{"key":"2026032106200674100_ref83","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1177\/0269881115576688","article-title":"Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms","volume":"29","author":"McCutcheon","year":"2015","journal-title":"J Psychopharmacol"},{"key":"2026032106200674100_ref84","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.schres.2025.09.032","article-title":"Duration of active psychosis: a scoping review of definition, measurement, and relationship with outcomes","volume":"285","author":"Crowley","year":"2025","journal-title":"Schizophr Res"}],"container-title":["Schizophrenia Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/52\/2\/sbag017\/67454600\/sbag017.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/52\/2\/sbag017\/67454600\/sbag017.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T10:20:27Z","timestamp":1774088427000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article\/doi\/10.1093\/schbul\/sbag017\/8532619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":84,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,3,21]]},"published-print":{"date-parts":[[2026,3,7]]}},"URL":"https:\/\/doi.org\/10.1093\/schbul\/sbag017","relation":{},"ISSN":["0586-7614","1745-1701"],"issn-type":[{"value":"0586-7614","type":"print"},{"value":"1745-1701","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,3]]},"article-number":"sbag017"}}